Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16992
Title: Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
Authors: Petrella, Teresa M;Robert, Caroline;Richtig, Erika;Miller, Wilson H Jr;Masucci, Giuseppe V;Walpole, Euan;Lebbe, Celeste;Steven, Neil;Middleton, Mark R;Hille, Darcy;Zhou, Wei;Ibrahim, Nageatte;Cebon, Jonathan S
Issue Date: Nov-2017
EDate: 2017-10-04
Citation: European Journal of Cancer 2017; 86: 115-124
Abstract: OBJECTIVE: Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma. PATIENTS AND METHODS: Patients received pembrolizumab 10 mg/kg every 2 (Q2W) or every 3 weeks (Q3W) for up to 2 years, or four cycles of ipilimumab 3 mg/kg Q3W. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) was administered at baseline and throughout the study. Patient-reported outcome (PRO) analyses were pre-specified exploratory endpoints; the primary PRO assessment was the score change from baseline to week 12 in EORTC QLQ-C30 global health status (GHS)/HRQoL score between the arms using constrained longitudinal data analysis. RESULTS: The PRO analysis population included 776 patients: pembrolizumab Q2W (n = 270); pembrolizumab Q3W (n = 266); ipilimumab (n = 240). Baseline GHS was similar across arms. QLQ-C30 compliance rates at week 12 were 87% (n = 214), 97% (n = 226), and 96% (n = 178), for the pembrolizumab Q2W, pembrolizumab Q3W, and ipilimumab arms, respectively. From baseline to week 12, GHS/HRQoL scores were better maintained with pembrolizumab than with ipilimumab (decrease of -1.9 and -2.5 for pembrolizumab versus -10.0 for ipilimumab; p < 0.001 for each pembrolizumab arm versus ipilimumab). Fewer patients treated with pembrolizumab experienced deterioration in GHS at week 12 (31% for pembrolizumab Q2W; 29% for Q3W and 44% for ipilimumab), with similar trends observed for individual functioning and symptoms scales. CONCLUSIONS: HRQoL was better maintained with pembrolizumab than with ipilimumab in patients with ipilimumab-naive advanced melanoma. CLINICALTRIALS. GOV IDENTIFIER: NCT01866319.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16992
DOI: 10.1016/j.ejca.2017.08.032
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/28987768
Type: Journal Article
Subjects: Advanced melanoma
EORTC QLQ-C30
Health-related quality of life
KEYNOTE-006
Patient-reported outcomes
Pembrolizumab
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.